The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The archive
Page 63 of 170 of this archive, newest first.
Brazil health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
SURMOUNT-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Who chose the vial that was tested?
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
A document, not a test: what a certificate actually is
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
Which results should be repeated before they are investigated
Timing is the whole of the post-cessation panel: draw it too early and it measures the treatment period.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Hong Kong: 18 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 35% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
STEP 1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A supplier suspends shipping to Argentina after 6 consecutive customs detentions
The route did not close because of a rule about peptides.
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A named analyst is the cheapest quality signal in this trade
Two signatures — one who performed the work, one who approved its release — are the ordinary regulated convention and are almost unknown here.
The mechanism behind the mechanism
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
LEADER misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
The relabeller trading as Vantris Bio closes after 24 years
A proper account of an operation that existed, and of what closing it cost.
VendorInvestigate result on a Wuhan mazdutide lot lands 3.4 points below the supplier’s figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
We asked four laboratories for a sterility test. Here is what came back.
A compendial sterility test takes fourteen days of incubation and consumes the containers tested. That timescale is incompatible with the business model that made…
Why "muscle-sparing" is a marketing term and not a measurement
Grading six widely repeated claims against the studies actually behind them.
TRIUMPH-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Canada pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
Independent analysis puts a QSC liraglutide lot at 99.2%, against 97.6% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Escalating onto a rising curve
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
The certificate says 2025. The vial in your hand does not say anything.
The interval between manufacture and analysis is the most under-read figure on the page, and the one most likely to matter by the time a vial is opened.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.